Home » Newsletters » BioWorld Science

BioWorld Science

June 9, 2021

View Archived Issues

Nippon Shinyaku patents muscarinic acetylcholine M3 receptor positive allosteric modulators

New mucolipin-1 activators identified at Libra Therapeutics

Suzhou Zelgen Biosciences divulges Toll-like receptor 7/8 agonists

New PDE6C and PDE5A inhibitors discovered at ILDONG Pharmaceutical

Yuhan Corp. and Green Cross Corp. present ceramide glucosyltransferase inhibitors

GS-3583 well tolerated, expands dendritic cells in healthy subjects

First-in-human study shows anti-ICOS KY-1044 well tolerated alone and with atezolizumab

Aivita presents phase II data for its personalized GBM vaccine candidate, AV-GBM-1

Phase Ib data indicate ST-617 can reduce severity of OM in patients receiving chemoradiation

Promising interim phase I and II data for BION-1301 in patients with IgA nephropathy

Early phase II results presented for ponatinib plus blinatumomab combination in Ph+ ALL patients

Stress sensor DJ-1 can heighten or dampen inflammation

DZD-9008 shows antitumor activity in NSCLC patients with EGFR exon20 insertion mutations

FDA approves IND for first-in-human study of CPI-300 in advanced tumors

Icosavax begins dosing in phase I/II trial of IVX-411 for COVID-19

Arena begins phase II study of temanogrel for coronary microvascular obstruction

PDS-0101, M-9241 and bintrafusp alfa combination in advanced HPV16-positive malignancies

Aclaris reports topline phase IIa data on ATI-1777 in moderate to severe atopic dermatitis

Cardiff Oncology initiates phase II trial of onvansertib for metastatic pancreatic cancer

A new selective, reversible BTK inhibitor bearing an imidazo[4,5-b]pyridine scaffold

Intracellular nanobody delivery for the treatment of intracellular Ehrlichia chaffeensis infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...